



Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

February 18, 2025

Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025

GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2024.

Participants can access the conference call live via [webcast](#), and also by visiting the [investors](#) page of Emergent's website. To participate via telephone, please register in advance at this [link](#). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the [investors](#) page of Emergent's website.

Additional Investor Event – Webcast Information

Emergent will also provide a brief presentation and remarks during J.P. Morgan's 2025 Leveraged Finance Conference. Participants may access the presentation via [webcast](#) at 11:00 am eastern time on Monday, February 24, 2025.

About Emergent BioSolutions

At Emergent, our mission is to protect and enhance life. For over 25 years, we've been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our [website](#) and follow us on [LinkedIn](#), [X](#), [Instagram](#), [Apple Podcasts](#) and [Spotify](#).

Investor Contact:

Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:

Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com



Source: Emergent BioSolutions